Affimed N.V. (NASDAQ:AFMD) Shares Shorted Decreased By 14.84%

Change of 14.84% for Affimed N.V. (NASDAQ:AFMD)’s shorted shares was registered. In March was issued AFMD’s total 1.62M shorted shares by FINRA. Previously was reported down change of 14.84% from 1.90M shares. 6 days will cost AFMD with 271,700 average volume to restore its previous position.

AFMD is touching $3.78 during the last trading session, after increased 3.56%.Affimed N.V. is uptrending after having risen 56.99% since March 6, 2018. AFMD has 525,127 volume or 2.03% up from normal. AFMD outperformed by 52.62% the S&P 500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally.The company has $235.98 million market cap. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.Currently it has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

For more Affimed N.V. (NASDAQ:AFMD) news published briefly go to:,,, or The titles are as follows: “Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial – Seeking Alpha” published on December 12, 2018, “Affimed (NASDAQ:AFMD) Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data – Benzinga” on June 15, 2018, “Affimed: Promising, Undervalued Immunotherapy Play With Multiple Catalysts Ahead – Seeking Alpha” with a publish date: December 06, 2018, “Affimed up 11% – Seeking Alpha” and the last “Affimed Clinical Hold Likely To Be Resolved Soon – Seeking Alpha” with publication date: November 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.